Late-stage biotech GID BIO wins funding from Richard King Mellon Foundation to study regenerative medicine as a potential therapeutic for severe respiratory distress Study to treat hospitalized COVID-19 patients applies...
Mergermarket is the leading provider of forward-looking M&A intelligence and data to investment banks, private equity firms, law firms, accounting firms, corporates and other M&A professionals around the world. WWW.MERGERMARKET.COM...
GID BIO completed an FDA compliant, multi-site, randomized, placebo-controlled Phase IIb clinical trial using autologous stromal cells in the treatment of knee osteoarthritis (OA), successfully meeting endpoints and two-year safety...